09:46 AM EST - Miraculins Inc. : has recently received important feedback from the United States Food and Drug Administration (FDA) as part of the de novo pre-submission process. Based on this communication from the FDA, Miraculins plans to continue advancing on the de novo clearance pathway for the Scout® device. Miraculins Inc.
shares V.MOM are trading up $0.01 at $0.13.
